Literature DB >> 23354389

Human HDL containing a novel apoC-I isoform induces smooth muscle cell apoptosis.

Catherine J McNeal1, Subroto Chatterjee, Jennifer Hou, London S Worthy, Craig D Larner, Ronald D Macfarlane, Petar Alaupovic, Robert W Brocia.   

Abstract

AIMS: We discovered that some adults with coronary heart disease (CHD) have a high density lipoprotein (HDL) subclass which induces human aortic smooth muscle cell (ASMC) apoptosis in vitro. The purpose of this investigation was to determine what properties differentiate apoptotic and non-apoptotic HDL subclasses in adults with and without CHD. METHODS AND
RESULTS: Density gradient ultracentrifugation was used to measure the particle density distribution and to isolate two HDL subclass fractions, HDL2 and HDL3, from 21 individuals, including 12 without CHD. The HDL fractions were incubated with ASMCs for 24 h; apoptosis was quantitated relative to C2-ceramide and tumour necrosis factor-alpha (TNF-α). The observed effect of some HDL subclasses on apoptosis was ∼6-fold greater than TNF-α and ∼16-fold greater than the cell medium. We observed that apoptotic HDL was (i) predominately associated with the HDL2 subclass; (ii) almost exclusively found in individuals with a higher apoC-I serum level and a novel, higher molecular weight isoform of apoC-I; and (iii) more common in adults with CHD, the majority of whom had high (>60 mg/dL) HDL-C levels.
CONCLUSIONS: Some HDL subclasses enriched in a novel isoform of apoC-I induce extensive ASMC apoptosis in vitro. Individuals with this apoptotic HDL phenotype generally have higher apoC-I and HDL-C levels consistent with an inhibitory effect of apoC-I on cholesteryl ester transfer protein activity. The association of this phenotype with processes that can promote plaque rupture may explain a source of CHD risk not accounted for by the classical risk factors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23354389      PMCID: PMC3598419          DOI: 10.1093/cvr/cvt014

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  48 in total

1.  Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy.

Authors:  Natacha Bellanger; Zélie Julia; Elise F Villard; Petra El Khoury; Emilie Duchene; M John Chapman; Natalie Fournier; Wilfried Le Goff; Maryse Guerin
Journal:  Atherosclerosis       Date:  2012-01-04       Impact factor: 5.162

Review 2.  Metabolic and functional relevance of HDL subspecies.

Authors:  Bela F Asztalos; Mariko Tani; Ernst J Schaefer
Journal:  Curr Opin Lipidol       Date:  2011-06       Impact factor: 4.776

3.  Detection of two distinct forms of apoC-I in great apes.

Authors:  Donald L Puppione; Christopher M Ryan; Sara Bassilian; Puneet Souda; Xinshu Xiao; Oliver A Ryder; Julian P Whitelegge
Journal:  Comp Biochem Physiol Part D Genomics Proteomics       Date:  2010-03       Impact factor: 2.674

4.  Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis.

Authors:  Jimmy F P Berbée; Caroline C van der Hoogt; Robert Kleemann; Emile F Schippers; Richard L Kitchens; Jaap T van Dissel; Irma A J M Bakker-Woudenberg; Louis M Havekes; Patrick C N Rensen
Journal:  FASEB J       Date:  2006-08-25       Impact factor: 5.191

5.  High-density lipoproteins: marker of cardiovascular risk and therapeutic target.

Authors:  Peter P Toth; Michael H Davidson
Journal:  J Clin Lipidol       Date:  2010-08-17       Impact factor: 4.766

Review 6.  The complexity of HDL.

Authors:  Gordon A Francis
Journal:  Biochim Biophys Acta       Date:  2010-08-21

7.  Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity.

Authors:  T Gautier; D Masson; J P de Barros; A Athias; P Gambert; D Aunis; M H Metz-Boutigue; L Lagrost
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

8.  Gender and racial differences in lipoprotein subclass distributions: the STRRIDE study.

Authors:  Johanna L Johnson; Cris A Slentz; Brian D Duscha; Gregory P Samsa; Jennifer S McCartney; Joseph A Houmard; William E Kraus
Journal:  Atherosclerosis       Date:  2004-10       Impact factor: 5.162

9.  APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians.

Authors:  Piya Lahiry; Henian Cao; Matthew R Ban; Rebecca L Pollex; Mary Mamakeesick; Bernard Zinman; Stewart B Harris; Anthony J G Hanley; Murray W Huff; Philip W Connelly; Robert A Hegele
Journal:  J Lipid Res       Date:  2009-10-06       Impact factor: 5.922

10.  High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1.

Authors:  Naoki Terasaka; Nan Wang; Laurent Yvan-Charvet; Alan R Tall
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

View more
  4 in total

Review 1.  Cholesteryl Ester Transfer Protein Inhibitors - Future Soon to be REVEALed.

Authors:  Christopher Huggins; Nicoletta Charolidi; Gillian W Cockerill
Journal:  Eur Cardiol       Date:  2015-07

2.  Proteogenomic Review of the Changes in Primate apoC-I during Evolution.

Authors:  Donald Puppione; Julian P Whitelegge
Journal:  Front Biol (Beijing)       Date:  2013-10-02

3.  Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry.

Authors:  Dongjian Song; Lifang Yue; Junjie Zhang; Shanshan Ma; Wei Zhao; Fei Guo; Yingzhong Fan; Heying Yang; Qiuliang Liu; Da Zhang; Ziqiang Xia; Pan Qin; Jia Jia; Ming Yue; Jiekai Yu; Shu Zheng; Fuquan Yang; Jiaxiang Wang
Journal:  Cancer Biol Ther       Date:  2016-06-03       Impact factor: 4.742

4.  Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study.

Authors:  Michelle Hilbert; Peter Kuzman; Wolf C Mueller; Jürgen Meixensberger; Ulf Nestler
Journal:  Sci Rep       Date:  2022-10-10       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.